Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. 1993

G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.

Allelic loss studies have been instrumental in identifying tumor suppressor gene loci in a variety of cancers. In this study we analyzed prostate cancer specimens from 52 patients for allelic loss using 8 polymorphic probes for the short arm of chromosome 8. Overall, 32 of 51 (63%) informative tumors showed loss of at least one locus on chromosome 8p. The most frequently deleted region is observed at chromosome 8p22-8p21.2. Loss of one allele is identified in 14 of 23 (61%) tumors at D8S163, in 15 of 32 (47%) tumors at lipoprotein lipase, and in 20 of 29 (69%) tumors at MSR, all on 8p22. Loss of one allele is identified in 16 of 27 (59%) tumors at D8S220 at 8p21.3-8p21.2. In addition to frequent loss of one allele at the MSR locus, one metastatic prostate cancer sample demonstrated homozygous deletion of MSR sequences. Loci telomeric and centromeric to this region are largely retained. A chromosome 8p deletion map is constructed and defines the smallest region of overlap to a 14-cM interval at 8p22 between D8S163 and lipoprotein lipase, flanking the MSR locus. Evidence of chromosome 8q multiplication at locus D8S39 was detected in 5 of 32 (16%) tumors, all of which demonstrated loss with at least one probe on chromosome 8p. This study extends the previous finding of frequent loss of chromosome 8p in prostate cancer by defining a common region of loss of heterozygosity at 8p22 and a homozygous deletion of the MSR locus contained within this region. This is the first homozygous deletion identified in the genome of a human prostate cancer and the highest rate of loss yet reported on chromosome 8p in cancer. These results strongly suggest the presence of a tumor suppressor gene in this region which is frequently inactivated in prostate cancer.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002898 Chromosomes, Human, Pair 8 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 8
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein

Related Publications

G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
January 1999, International journal of cancer,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
July 1996, Genomics,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
October 2000, International journal of cancer,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
November 1994, Genomics,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
July 1994, Genes, chromosomes & cancer,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
April 1994, Cancer research,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
March 1998, Genes, chromosomes & cancer,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
October 1997, Clinical cancer research : an official journal of the American Association for Cancer Research,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
June 1999, International journal of cancer,
G S Bova, and B S Carter, and M J Bussemakers, and M Emi, and Y Fujiwara, and N Kyprianou, and S C Jacobs, and J C Robinson, and J I Epstein, and P C Walsh
July 1997, International journal of cancer,
Copied contents to your clipboard!